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Abstract 
Sepsis occurs frequently in the intensive care unit (ICU) and is a leading cause of 
admission, mortality, and cost. Treatment guidelines recommend early intervention, 
however positive blood culture results may take up to 48 hours. Insulin sensitivity (SI) is 
known to decrease with worsening condition and could thus be used to aid diagnosis. 
Some glycemic control protocols are able to accurately identify insulin sensitivity in real-
time. 
Hourly model-based insulin sensitivity SI values were calculated from glycemic control 
data of 36 patients with sepsis. The hourly SI is compared to the hourly sepsis score (ss) 
for these patients (ss = 0-4 for increasing severity). A multivariate clinical biomarker was 
also developed to maximize the discrimination between different ss groups. Receiver 
operator characteristic (ROC) curves for severe sepsis (ss ≥ 2) are created for both SI and 
the multivariate clinical biomarker. 
Insulin sensitivity as a sepsis biomarker for diagnosis of severe sepsis achieves a 50% 
sensitivity, 76% specificity, 4.8% positive predictive value (PPV), and 98.3% negative 
predictive value (NPV) at an SI cut-off value of 0.00013 L/mU/min. Multivariate  clinical 
biomarker combining SI, temperature, heart rate, respiratory rate, blood pressure, and 
their respective hourly rates of change achieves 73% sensitivity, 80% specificity, 8.4% 
PPV, and 99.2% NPV. Thus, the multivariate clinical biomarker provides an effective 
real-time negative predictive diagnostic for severe sepsis. Examination of both inter- and 
intra-patient statistical distribution of this biomarker and sepsis score shows potential 
avenues to improve the positive predictive value. 
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1. INTRODUCTION 
 
Sepsis presents a serious medical problem in the adult intensive care unit (ICU) around 
the world, with a 11-15% incidence of severe sepsis, 30-60% mortality rate, $22,100 
USD average cost per case, $16.7 billion USD annual total cost, and 1.5% projected 
annual incidence increase [1]. Sepsis treatment guidelines and patient management 
protocols recommend early goal-directed resuscitation of the septic patient during the 
first 6 hours after infection recognition [2]. Currently, blood bacteria cultures are 
considered the gold standard for confirmation of infection. However, only 51% of sepsis 
cases are positively identified as cultured pathogens [3]. 
Early interventions have been documented to reduce mortality from 46.5% to 30.5% [4]. 
In addition, a landmark clinical trial implementing a blood glucose control protocol 
resulted in a reduction in the incidence of sepsis [5]. Currently available biomarkers, such 
as procalcitonin (PCT), provide sepsis diagnostic test results in 2-3 hours with 
commercially available kits, but to various levels of clinical accuracy [6]. 
A clinically validated glucose-insulin model that is able to model insulin sensitivity (SI) 
in real-time has been used to develop blood glucose protocols for critically ill patients [7, 
8]. An integral-based parameter identification method has been used to fit the data [9]. 
The model-based SI has been observed to indicate the severity of illness and metabolic 
status, as well as being validated against euglycaemic clamp data [10]. Insulin sensitivity 
has also been previously documented as decreasing with worsening condition [11], and 
increasing with improvement [12, 13]. 
This study aims to evaluate the relationship of modelled insulin sensitivity [7, 14] and 
patient condition. In particular, this study examines using the modelled insulin sensitivity 
as a marker for real-time diagnosis and differentiation of Systemic Inflammatory 
Response Syndrome (SIRS) and sepsis in a cohort of adult ICU patients. It extends the 
work of Blakemore et al. [15] by increasing discrimination and utilizing additional 
clinical measurements. 
 
 
2. METHODS 
2.1  Physiological glucose-insulin model 
The physiological glucose-insulin model for clinically ill patients has one compartment 
for plasma glucose, two compartments for insulin kinetics, and a two-compartment 
dextrose absorption model. 
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Equation (1) represents the plasma glucose compartment where G is the blood glucose 
level. Equation (2) describes the plasma insulin compartment where I is the plasma 
insulin level. Equation (3) describes insulin action in interstitial space where Q is the 
interstitial insulin level. Equations (4)-(6) describe the absorption of dextrose intake 
(D(t)) through stomach (compartment P1) and gut (compartment P2) and its appearance 
into plasma (P(t)).  The transport of glucose from gut to the blood stream is saturable, and 
the maximum transport rate is Pmax. 
Endogenous glucose production (EGP) for a healthy subject varies throughout a day 
according to daily activities, food intake and stress response etc. On a pharmacodynamics 
level, EGP is suppressed with increasing G and Q. Time-varying EGP is difficult to 
measure clinically and cannot be uniquely identified in this study. Therefore this model 
uses a constant term EGPb in Equation (1) to represent the basal endogenous glucose 
production for a patient under no presence of glucose or insulin. Insulin independent 
glucose removal (excluding central nervous system uptake CNS) and the suppression of 
EGP from EGPb with respect to G are represented with pG. In contrast, insulin mediated 
glucose removal and the suppression of EGP from EGPb due to GLUT4 (which action is 
associated with the compounding effect of receptor-binding insulin and blood glucose) is 
represented with SI. Insulin sensitivity (SI) is time varying and reflects evolving patient 
condition. 
In Equation (3), the exogenous insulin administration into plasma insulin is uex(t). Plasma 
insulin decay rate is n and VI is the plasma insulin distribution volume. Endogenous 
insulin production is expressed by 
 
e−kI uex t( )IB , where IB is the basal insulin production 
when no exogenous insulin is present. Endogenous insulin production is suppressed 
exponentially with exogenous insulin. Table 1 is a nomenclature for all the parameters, 
symbols and abbreviation used in this article. 
This model is an improvement from the model used in [15]. This model has an additional 
CNS for glucose uptake as this uptake is found to be very consistent inter- and intra-
individuals. Dextrose absorption model describes by Equations (4)-(6) is more 
physiological and universal compare to the simple feed model in [15]. The simple feed 
model in [15] requires the enteral feeding be relatively constant (not changing more 
frequently than every 2 hours), whereas the dextrose absorption model presented here is 
generic and applicable even for modelling meal intake. Finally, this model has an 
endogenous insulin term 
 
e−kI uex t( )IB  to ensure the entire differential equations model in 
Equations (1)-(6) is not ill-conditioned when there is no exogenous insulin given over a 
significant period of time. 
 
Table 1. Nomenclature 
αG Saturation parameter for insulin mediated 
glucose removal 
(L/mU) 
αI Saturation parameter for insulin clearance 
from plasma 
(L/mU) 
CDF Cumulative distribution function  
CNS Central nervous system glucose uptake (mmol/min) 
D(t) Dextrose intake (mmol/min) 
d1 Glucose absorption rate from stomach (min-1) 
d2 Glucose absorption rate from gut (min-1) 
EGP Endogenous glucose production  
EGPb Basal endogenous glucose production rate (mmol/min) 
FN False negative  
FP False positive  
G Blood glucose level (mmol/L) 
GLUT Glucose transporters  
ICU Intensive Care Unit  
I Plasma insulin level (mU/L) 
IB Basal endogenous insulin production rate (mU/min/L) 
k Interstitial insulin transport rate (min-1) 
k1 Exponential suppression of endogenous 
insulin production constant 
 
n Plasma insulin decay rate (min-1) 
NPV Negative predictive value  
P(t) Glucose appearance in plasma from 
dextrose intake 
(mmol/min) 
P1 Glucose level in stomach (mmol) 
P2 Glucose level in gut (mmol) 
PCT procalcitonin  
PDF Probability density function  
pG Insulin independent glucose removal 
(excluding central nervous system uptake) 
and the suppression of EGP from EGPb 
with respect to G 
(min-1) 
Pmax Maximal glucose flux from gut to plasma (mmol/min) 
PPV Positive predictive value  
Q Interstitial insulin level (mU/L) 
ROC Receiver operator characteristic  
SI Insulin mediated glucose removal and the 
suppression of EGP from EGPb with 
respect to G and Q 
(L/mU/min) 
SIRS Systemic inflammatory response score  
SOFA Sepsis-related organ failure assessment  
ss Sepsis score  
TN True negative  
TP True positive  
uex(t) Exogenous insulin (mU/min) 
VI Plasma insulin distribution volume (L) 
VG Plasma glucose distribution volume (L) 
 
2.2  Sepsis score (ss) criteria and analysis 
Sepsis is a systemic inflammatory response syndrome (SIRS) due to infection [16]. In 
this study, sepsis is defined using the clinical classification score (ss) provided by the 
ACCP/SCCM guideline definitions [17]. The criteria are defined in Tables 2-4, which 
include SIRS and the Sepsis-related Organ Failure Assessment (SOFA) score [18]. 
Table 2. SIRS criteria 
score Criteria 
+ 1 temperature < 36º C > 38º C 
+ 1 heart rate > 90/min 
+ 1 respiratory rate or PaCO2 
> 20/min 
< 32 mm Hg 
+ 1 white blood cell count 
< 4 x 109/L or > 12 x 109/L or 
presence of > 10% immature 
granulocytes 
 
Table 3. SOFA criteria 
score system criteria 
+ 1 cardiovascular 
MAPa or 
need for 
inotropes 
< 60 mm Hg 
+ 1 respiratory PaO2/FiO2 
<250 mm Hg/mm 
Hg 
<200 mm Hg/mm 
Hg with pneumonia 
+ 1 renal Urine output < 0.5 ml/kg/h 
+ 1 blood platelets < 80 x 10
9/L or 50% 
drop in 3 days 
aMean arterial pressure 
 
Table 4. Sepsis score (ss) criteria 
sepsis score SIRS > 2 
Infection 
during 
stay 
organ failure > 1 fluid resuscitation inotrope present 
high 
inotrope 
dosea 
0 normal       
1 sepsis X X     
2 severe sepsis X X X X   
3 septic shock X X X X X  
4 refractory septic shock X X X X X X 
aadrenaline or noradrenaline > 0.2 mg min-1 kg-1 
 
Clinical data was gathered for n = 36 sepsis patients admitted to the medical ICU in 
Christchurch Hospital (Christchurch, New Zealand). Each patient was on the SPRINT 
blood glucose control protocol [13], providing 9208 total patient hours of hourly 
modelled insulin sensitivity. The hourly SI was compared to SIRS and ss data. Note that 
each stay included periods of sepsis and without sepsis (ss = 0). These periods are 
differentiated by positive blood culture and SIRS ≥ 2, and thus ss ≥ 1. 
Receiver Operator Characteristic (ROC) curves were used to examine the performance of 
SI as a diagnostic marker for sepsis. ROC curves effectively examine the ability of the 
biomarker to differentiate between populations. Sensitivity, specificity, positive 
predictive value (PPV), and negative predictive value (NPV) were also evaluated. ROC 
curves effectively examine the separation between normal and diseased populations in 
terms of probability density functions (PDF). Variablility of ss score from one hour to the 
next hour were also examined. 
Therefore, other clinical measurements were evaluated and combined with SI to create a 
biomarker that aims to maximise the PDF separation or discrimination in normal and 
septic groups. The biomarker was created as an hourly changing function based on hourly 
SI and clinical measurements. A linear recursive least square method was used to 
maximize the discrimination between populations. Optimal weighing functions were 
chosen using the Optimization Toolbox in MatlabTM. The specific goal was to provide 
discrimination for ss ≥ 2, where prior studies [15] only achieved it for ss ≥ 3. Achieving 
this goal for the lower ss = 2 value will provide a marker for a larger group of patients.  
Ideally, cross validation or bootstrapping should be performed on the data to avoid 
overfitting. However, because the current available data is very limited (36 patients), the 
same data is used for both developing the biomarker and testing it. In particular, the low 
prevalence of high sepsis score hours limits the ability to boot strap or cross validate 
effectively. Equally, it should be noted the work presented in this study is more of a 
proof-of-concept study to justify a larger, more costly comprehensive validation study, 
rather than a comprehensive large scale validation. The method used in this work is novel 
in the field of sepsis diagnosis, to the best of the authors’ knowledge. Finally, sepsis 
patient data used in this study is a subset from a cohort representative of typical intensive 
care patients [13].  
 
 
3. RESULTS AND DISCUSSION 
 
Table 5 shows the total hours at each sepsis score. The majority of the hours are at ss < 2. 
Table 5. Patient hours by sepsis score (ss) 
sepsis 
score (ss) 0 1 2 3 4 
patient 
hours 
4186 
(45.1%) 
4861 
(52.3%) 
91 
(1.0%) 
88 
(0.9%) 
60 
(0.6%) 
3.1  Insulin sensitivity (SI) and sepsis score (ss) 
Figure 1 shows a cumulative distribution function (CDF) plot of SI, for each ss group. SI 
is generally lower for more severe sepsis. However, the distinction between the septic (ss 
≥ 1) and non-septic (ss = 0) groups is not clear. 
 
Fig. 1. Cumulative distribution function (CDF) of insulin sensitivity 
(SI), grouped by sepsis score (ss). 
 
3.2  Insulin sensitivity SI as a biomarker 
Figure 2 shows the ROC curve for SI as a sepsis biomarker. There is minimal 
discrimination between no sepsis (ss = 0) and a sepsis score of ss = 1. For ss ≥ 2, an S I 
cut-off value of 0.00013 L/mU/min achieves a 50% sensitivity, 76% specificity, 4.8% 
PPV, and 98.3% NPV. 
Even though SI is generally lower at higher ss values, the distribution of SI for each ss 
group overlaps too much in Figure 1 with the non septic group. Therefore, using SI level 
itself is not a completely effective sepsis biomarker.  
 
 
Fig. 2. Receiver operator characteristic (ROC) curve for SI as a sepsis 
biomarker, grouped by sepsis score (ss), with cutoff points (x). 
 3.3 Multivariate clinical biomarker utilising SI 
Figure 3 shows the CDF of a biomarker combining SI and other clinical factors, for each 
ss group. The clinical measurements used in the biomarker include temperature, heart 
rate, respiratory rate, blood pressure, and their respective rates of change. The 
multivariate biomarker generally decreases with increasing sepsis severity. The 
discrimination between sepsis and non-septic groups is improved, as compared to Figure 
1 using SI only as a diagnostic test. 
 
 
Fig. 3. Cumulative distribution function (CDF) of the clinical 
biomarker, grouped by sepsis score (ss). 
 
Figure 4 shows the ROC curve for this biomarker. For ss ≥ 2, the biomarker achieves 
73% sensitivity, 80% specificity, 8.4% PPV, and 99.2% NPV. The addition of clinical 
measurements with SI significantly improved the diagnostic test performance for sepsis, 
as compared to using SI alone. In particular, the biomarker provides an effective negative 
predictive diagnosis for severe sepsis (ss = 2), which was not achieved previously. 
It is also clear comparing Figure 2 and Figure 4 that the discrimination between ss = 1 
and ss ≥ 2 is now wider. Note that ss = 1 is difficult to discriminate from ss = 0 and 
simple, clinical SIRS. Hence, as seen in Figure 2 and Figure 4, its discrimination from ss 
= 0 is still marginal. 
 
Fig. 4. Receiver operator characteristic (ROC) curve for the 
multivariate clinical biomarker, grouped by sepsis score (ss), with 
cutoff points (x). 
Table 6 is a contingency table showing the biomarker diagnostic outcome for ss ≥ 2.
There are 9208 total hours of patient data. This data is classified into four categories 
using sepsis score and biomarker test outcome: true positive (TP, n = 165), false positive 
(FP, n = 1802), false negative (FN, n = 61), and true negative (TN, n = 7180). There are 
8982 hours when ss < 2 and 226 hours when ss ≥ 2. Using the biomarker,  7241 hours test 
negative and 1967 hours test positive. 
Table 6. Contingency table 
 ss ≥ 2 226 hours 
ss < 2 
8982 hours  
test positive 
1967 hours 
TP = 165 
(1.8%) 
FP = 1802 
(19.6%) 
PPV 
8.4% 
test negative 
7241 hours 
FN = 61 
(0.7%) 
TN = 7180 
(78%) 
NPV 
99.2% 
total 
9208 hours 
sensitivity 
73.0% 
specificity 
79.9%  
 
Note that these ratios also indicate the relative incidence and reflect clinical expectations 
where, by the hour, most sepsis is not necessarily severe. This last point is critical as most 
sepsis incidence is recorded by patients. By patient, the incidence of severe sepsis is 5-
10% [1], which is reflected in this cohort. However, with rapid, aggressive treatment its 
incidence by hour is low. This low incidence is problematic in developing such a non-
invasive and real-time clinical biomarker. 
Figure 5 provides a visual presentation of clinical sepsis score and the biomarker 
performance. Most of the patient hours are ss < 2 (TN + FP). Even though the biomarker 
correctly identifies the severity of sepsis 73% of the time when ss ≥ 2 and 80% of the 
time when ss < 2, the PPV stays low because the ratio of TP to test positive is limited by 
the ratio between ss ≥ 2 to ss < 2. On contrast, NPV is inherently high because the ratio 
of TN makes up the majority of test negative. Again, the mathematics indicate that 
relatively low incidence by hour, as seen in the 8982 hours of ss < 2 and 4186 hours of ss 
= 0, hinders good PPV despite good specificity. 
 
Fig. 5. Histogram of clinical biomarker data, grouped by contingency 
results. 
3.4 Sepsis time course 
Figure 6 effectively shows the probability of how ss changes from one hour to the next. 
The horizontal axis is the current hour ss and the vertical axis is the ss for the next hour. 
The majority of the patient data is when ss = 0 and ss = 1. 
Patients at ss = 1 tend to stay at ss = 1, and patients having ss = 0 tend to stay at ss = 0. 
Interestingly, when ss ≥ 2, the highest probability is moving to ss = 1 in the next hour. 
This set of results shows that if sepsis is detected at ss ≥ 2, current rapid and agg ressive 
ICU treatments are usually very effective in reducing the severity of the inflammatory 
responses. 
 
Fig. 6. Scatter plot of clinical biomarker variation from hour to hour 
with respect to sepsis score (ss) (axis numbers = ss + biomarker/1000). 
 
3.5 Biomarker comparison 
The clinical informative values a biomarker may provide in sepsis are: detection of 
infection; diagnosis of SIRS severity and infection progression; and patient treatment 
guidance, responsiveness, and prognosis. One such investigated biomarker is 
procalcitonin (PCT), which was first found elevated in sepsis in 1993 [19]. PCT is a 
precursor of the hormone calcitonin, synthesized by thyroid C cells, but in sepsis has an 
extra-tyroidal origin. Upon intravenous injection of endotoxin from E. coli in healthy 
volunteers, serum PCT becomes detectable after 4 hours, maintaining a plateau through 8 
to 24 hours, following an increase of proinflammatory cytokines [20]. 
PCT can be measured from serum plasma by commercially available 
immunoluminometric assay kits such as LUMItest PCT (Brahms, Berlin, Germany) and 
Kryptor PCT (Brahms, Hennigsdorf, Germany). The use of PCT has been approved by 
the FDA “in conjunction with other laboratory findings and clinical assessments to aid in 
the risk assessment of critically ill patients on their first day of ICU admission for 
progression to severe sepsis and septic shock”. 
The reported diagnostic power of PCT from 25 studies using PCT (2,966 patients) as a 
diagnostic marker of sepsis, severe sepsis, or septic shock in the adult ICU or after 
surgery or multiple trauma, compared with nonseptic SIRS has sensitivity ranging from 
42% to 97% or even 100%, and specificity ranging from 48% to 100% [21]. Optimal 
cutoff values for PCT, determined from ROC curves, ranged from 0.6 to 5 ng/mL. 
PCT is generally only assessed once a day and thus cannot provide real-time detection. In 
contrast, the biomarker presented in this study is a real-time marker. In addition, all of 
these studies had some form of extensive clinical pre-screening for sepsis and/or SIRS, 
biasing the sensitivity or specificity. The overall results reported are no better, and often 
worse, than those reported here. 
Traditionally, diagnostic test results are based on a cut-off point. This method effectively 
treats all patients as a single, generic person with one clear cut-off point that distinguishes 
between normal and abnormal states. However, recent medical treatments have been 
moving towards patient customisation – tailoring treatments to patient needs [22]. 
Although this study has so far provided a sepsis biomarker that has a cut-off value which 
can differentiate ss ≥ 2 from ss < 2 most of the time, this biomarker is also a time-varying 
value. As with most clinical measurements, this biomarker would have both inter- and 
intra-patient statistical distribution. 
3.6 Future work 
It is therefore of interest to further investigate how this biomarker changes through time 
for patients, and how much variability there is between patients. A means of normalizing 
patients and likely changes using stochastic models would improve biomarker 
performance. An observational study and follow-up of a biomarker for sepsis diagnosis in 
the ICU would provide the data needed for that analysis. Finally, the statistical model of a 
biomarker, like the one developed in this paper, may be more useful clinically by 
providing a probability analysis of disease progression in real-time. 
 
4. CONCLUSIONS 
 
Insulin sensitivity as a sepsis biomarker for diagnosis of severe sepsis achieves a 50% 
sensitivity, 76% specificity, 4.8% PPV, and 98.3% NPV at an SI cut-off value of 0.00013 
L/mU/min. A discriminating threshold was not found between the ss = 0 and ss = 1 
cohorts due to a high degree of population overlap. A clinical biomarker combining SI, 
temperature, heart rate, respiratory rate, blood pressure, and the respective rate of change 
achieves 73% sensitivity, 80% specificity, 8.4% PPV, and 99.2% NPV, and thus can act 
as an effective negative predictive diagnosis for severe sepsis. 
PPV performance is poor because the ratio of true positive to test positive is limited by 
the ratio of hours where ss ≥ 2 to ss < 2. The majority of patient hours had ss < 2. 
However, the multivariate clinical biomarker may provide patient-specific diagnosis, and 
effectively show the probability of sepsis time course from hour to hour. Real-time 
results may aid in the treatment and management of sepsis in the ICU. Future work 
includes an observational study and follow-up of a biomarker for sepsis diagnosis in the 
ICU. 
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